Continuing evolution of the role of β-blockers in the treatment of hypertension
نویسنده
چکیده
The classifi cation of αand β-adrenoceptors by Ahlquist and colleagues in 1948 provided the foundation for the development of drugs that could modulate the sympathetic nervous system (SNS) [1]. The fi rst β-blocker, pronethalol, developed by Sir James Black, was limited clinically due to safety concerns. However, the subsequent development of its successor, propranolol, earned Black the Nobel Prize for Medicine in 1988, and revolutionized the process of the laboratory development of cardiovascular drugs [2]. The development of the β-blocking class of drugs provided clinicians with new tools to treat many cardiovascular disorders that now include: hypertension, heart failure, angina pectoris, certain arrhythmias, post-myocardial infarction ventricular dysfunction and high-risk patients, including those with diabetes mellitus [3–5]. The fi rst widely used β-blocker, propranolol, had equal blocking properties at both the β1 and β2 adrenoceptor subtypes. Since blocking β2 receptors produced unwanted side effects (e.g., vasoconstriction and bronchoconstriction), new (second-generation) drugs were developed that were more selective for the β1 receptor, for example, metoprolol and atenolol. These drugs were called cardioselective. However, at higher doses, blockade occurred at both receptors [6]. The traditional β-blocking drugs are associated with many side effects, including fatigue, sexual dysfunction (erectile dysfunction), cold hands and weight gain [7], and have limited effi cacy in obese patients [8]. Moreover, these traditional β-blockers have a propensity to increase insulin resistance and hasten the appearance of hyperglycemia (diabetes mellitus). Additionally, the use of β-blockers in African–American hypertensive patients may be limited owing to the fact that traditional β-blockers are less effective in lowering blood pressure (BP) in hypertensive African–American patients compared with hypertensive Caucasian patients [9,10]. The newer (‘third-generation’) β-blocking drugs are characterized by the ability to produce vasodilation, and include carvedilol, labetalol and nebivolol. Carvedilol and labetalol achieve vasodilation by interfering with the α1 adrenoceptor, whereas nebivolol utilizes a mechanism that is endothelial dependent and results in increased bioavailability of nitric oxide (NO) (vide infra).
منابع مشابه
Neonatal Hypertension: Etiology, Diagnosis and Management
Neonatal hypertension is a rare and complex condition, with an incidence rate of 0.2% to 3%. It can be resulted by several risk factors such as renal diseases, use of several drugs, neurologic, cardiac, respiratory and endocrine causes. Gestational age, birth weight and conceptual age are the most important risk factors. Renal diseases can be found in about 25% to 50% of hypertension at neonata...
متن کاملThe role of calcium channel blockers in wound healing
Wound healing is a natural response to restore the injured tissue to normal. Wound healing is also complicated process involving different cellular, molecular and biochemical mechanisms and various types of cytokines and growth factors. Calcium channel blockers belong to cardiovascular medicine and administrated to treatment of hypertension, angina and cardiac arrhythmia because of vasodilatory...
متن کاملSensitivity of Human Leukemic Cells to Carvedilol
Background and Objective: Carvedilol, a non-specific β-blocker, has been used for treatment of hypertension, stroke and congestive heart failure. The therapeutic effects of β blockers in cancer patients have been shown. Carvedilol has considerable anti-inflammatory, anti-tumor and anti-angiogenic properties. In this study, the effects of carvedilol on proliferation of human U937 and Molt-4 leuk...
متن کاملInvestigating the Consistancy Rate of Hypertension Treatment through Guide Line JNC-7, in Patients Who Were Referred to Health Centers and Health Houses of Fasa University of Medical Sciences 2012
Background & Objective: Choosing antihypertensive as a drug for treating hypertension is the most important part of its treatment. The present study was done in investigating the consistancy rate of hypertension treatment through Guide Line JNC-7 in patients who were referred to health centers and health houses of Fasa University of Medical Sciences in 2012. Materials & Methods: In thi...
متن کاملOral Manifestations of Patients Taking Anti-Hypertensive Medications
Background and Aim: High blood pressure is a common cardiovascular disease. Most cardiovascular medications have adverse oral side effects. This study aimed to determine the prevalence of oral manifestations associated with the intake of anti-hypertensive medications. Materials and Methods: This cross-sectional analytical study examined 142 patients with a history of hypertension referred to D...
متن کاملChiral recognition mechanisms of four β-blockers by HPLC with Amylose Chiral Stationary Phase
The high performance liquid chromatography (HPLC) enantioseparation of four β-blocking agents metoprolol, bisoprolol, propranolol and atenolol was performed on amylose tris-(3,5-dimethylphenylcarbamate) chiral stationary phase using n-hexane-ethanol-diethylamine (DEA) as the mobile phase and related chiral recognition mechanisms were discussed. Enantiomeric separation of the fourβ-blockers was ...
متن کامل